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ABSTRACT: The fungal metabolite, 3-chloro-4-hydroxyphenylacetic acid (1), was 
utilized in the generation of a unique drug-like screening library using parallel-
solution phase synthesis. A 20-membered amide library (3–22) was generated by first 
converting 1 to methyl(3-chloro-4-hydroxyphenyl)acetate (2) then reacting this 
scaffold with a diverse series of primary amines via a solvent-free aminolysis 
procedure. The structures of the synthetic analogues (3–22) were elucidated by 
spectroscopic data analysis. The structures of compounds 8, 12, and 22 were 
confirmed by single X-ray crystallographic analysis. All compounds were evaluated 
for cytotoxicity against a human prostate cancer cell line (LNCaP) and for 
antiparasitic activity towards Trypanosoma brucei brucei and Plasmodium falciparum 
and showed no significant activity at 10 M. The library was also tested for effects on 
the lipid content of LNCaP and PC-3 prostate cancer cells, and it was demonstrated 
that the fluorobenzyl analogues (12–14) significantly reduced cellular phospholipid 
and neutral lipid levels. 
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Natural products (NPs) have played a key role in drug discovery, which is reflected 
by the fact that numerous commercial drugs are either NPs, modified NPs, or 
compounds based on a NP pharmacophore.1-4 The success and impact of NPs in the 
pharmaceutical arena is due, in part, to the fact that these natural constituents have 
been biologically validated, since they have been selected during evolution to bind to 
biosynthetic enzymes.5-7 This inherent capacity of NPs to interact in biological space 
is thought to correlate with their ability to recognize therapeutic targets present in 
humans and/or other organisms (e.g., pathogenic microbes) that are associated with 
human diseases.5,8,9  
In regard to NP drug discovery, a scaffold is a basic structural element that 
contains mono- or poly-functional groups that can be exploited in the synthesis of 
chemically diverse and unique screening libraries. The ultimate goal of such libraries 
is the identification of hit or lead compounds [usually following high-throughput 
screening (HTS)] that can be further optimized using medicinal chemistry for 
potential preclinical development and beyond. The use of selected NP scaffolds as the 
starting points for the generation of novel libraries has been touted as a means by 
which NPs can impact present and future drug discovery and development 
programs.3,4,10-12 On the basis of this hypothesis, one of our current research 
objectives is the design and synthesis of “smarter” lead or drug-like screening 
libraries based on unique NP scaffolds isolated from Australian biota sources. To 
date, we have synthesized libraries based on the muurolane (source: plant),4 
tetrahydroanthraquinone (source: mushroom),13 tambjamine (source: ascidian)14 and 
3-chloro-4-hydroxyphenylacetic acid (1) (source: endophytic fungus)15 NP scaffolds. 
As part of our continuing research efforts in this field it was decided to evaluate 
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further and exploit the 3-chloro-4-hydroxyphenyl acetic acid (1) scaffold in medicinal 
chemistry studies.  
In this second generation library, careful consideration was given to the design 
aspect of the library, paying particular attention to creating molecules with desirable 
drug-like physicochemical properties, based on Lipinski’s “Rule of Five” criteria.16 
Furthermore, it was desired to investigate an alternative amidation reaction compared 
to the original library procedure,15 in an attempt to improve yields, and potentially 
simplify the reaction product work-up. The fungal NP, 3-chloro-4-hydroxyphenyl 
acetic acid (1), was first isolated from the endophytic microfungus Xylaria sp.17 
Although this NP has shown minimal activity towards human melanoma (MM96L) 
and prostate (DU145) cell lines,15 and carbonic anhydrase,15 the 3-chloro-4-
hydroxyphenyl motif present in 1 has been identified in a number of bioactive 
molecules such as (–)-xylariamide A,18 coniothyriomycin,19 and cryptophycin 53.20,21 
Owing to the limited biological profiling of the original 3-chloro-4-hydroxyphenyl 
acetic acid-derived library15 it was decided to make additional synthetic analogues for 
a more thorough evaluation in several biological assays.  
Herein the solution-phase parallel synthesis of a 20-membered amide library 
(3–22) using a derivative of the fungal metabolite, 3-chloro-4-hydroxyphenyl acetic 
acid (1) is reported. The biological evaluation of the library against malaria and 
trypanosome parasites, along with a prostate cancer cell lines is also described. 
 
A large percentage of NPs and synthetic compounds possess the amide 
functional group and it is also known that ~25% of clinical drugs contain this moiety 
thus making the amidation reaction the most commonly used reaction in medicinal 
chemistry.22 A number of reviews have been published demonstrating the use and 
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importance of coupling agents (e.g., HBTU, EDCI, CDI, and DCC) for amide 
formation.23,24 However, for the synthesis of this second generation amide library, an 
amidation reaction was used whereby the products were prepared by direct aminolysis 
of an ester with a range of primary amines under solvent-free conditions.25,26 The 
previous amidation study on the NP scaffold (1) reported the synthesis of a small 11-
membered library using EDCI coupling.15 Following liquid-liquid partitioning of the 
crude reaction product and silica flash chromatography, the yields from the EDCI first 
generation library ranged from 8 to 99%. 
Prior to commencing the synthesis of the second generation library, a 25-
membered virtual analogue (VA) library was constructed using a set of commercial 
amines. Using the software Instant JChem,27 the physicochemical parameters such as 
cLog P, hydrogen bond donors (HBD), hydrogen bond acceptors (HBA), and 
molecular weight (MW) of these VAs (VA1–VA20) were determined (see Supporting 
Information, Table S45 and Figure S46). The molecules with favourable 
physicochemical properties, based on Lipinski’s “Rule of Five” for drug-like 
molecules (MW < 500, HBD < 5, HBA < 10, cLog P < 5)16 (see Supporting 
Information Table S47) were prioritized for synthesis work. On the basis of the in 
silico data, VA1–VA20 were selected for synthesis since all these analogues had no 
“Rule of Five” violations.  
The synthetic route for the target amide analogues is shown in Scheme 1. The 
carboxylic acid moiety of the commercially available scaffold 1 was activated by 
esterification with anhydrous MeOH in the presence of p-toluenesulfonic acid 
(pTsOH) yielding methyl(3-chloro-4-hydroxyphenyl)acetate (2), which is more 
susceptible to aminolysis under mild conditions. Treatment of 2 with 20 primary 
amines afforded the secondary amides (3–22) as shown in Figure 1. Excess amine 
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was removed under N2 and/or by high vacuum after which the crude reaction mixture 
was pre-adsorbed onto silica gel and chromatographed using CH2Cl2-MeOH or 
CH2Cl2-MeOH-1% triethylamine (TEA) (see Experimental Section) to afford 
compounds 3–22 in moderate to good yields. Compounds 3 and 9 have been 
synthesized previously using EDCI as the coupling agent with the yields of 98% and 
69%, respectively.15 However, using the direct aminolysis method, 3 (73%) and 9 
(25%) were obtained in reduced yields when compared to the EDCI coupling 
procedure. Despite the lower yields, direct aminolysis under solvent-free conditions 
proved to be a simple and clean reaction that avoided the use of coupling reagents and 
complicated work-up procedures. Thus, this methodology is well suited for 
combinatorial chemistry studies using the scaffold, methyl(3-chloro-4-
hydroxyphenyl)acetate (2). 
The structures of all the amide analogues (3–22) were determined following 
1D (1H and 13C) and 2D NMR (gCOSY, gHSQC, gHMBC) and HRESIMS data 
analysis. Slow evaporation of solutions of 8, 12, and 22 in CH2Cl2 resulted in crystals 
suitable for X-ray diffraction. Therefore, the structures of compounds 8, 12, and 22 
were also confirmed by X-ray crystallography (see Figure 2 and Supporting 
Information S48 and Figure S49). 
 Owing to an ongoing interest in the discovery and development of novel small 
molecules that have potential anticancer28-30 and/or anti-infective31-33 properties the 
library (3–22) was profiled along with the NP scaffold (1), and methyl ester derivative 
(2) against a human prostate cancer cell line (LNCaP),28 as well as Trypanosoma 
brucei brucei34 and Plasmodium falciparum.35 These in vitro assays showed that none 
of the compounds displayed significant activity (>50% inhibition) after 72 h at 10 
M. Additionally, all the analogues were also tested at 10 M for effects on the lipid 
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content of LNCaP cells by staining with the lipophilic fluorescent dye Nile Red and 
fluorescence microscopy. The fluorescence intensity of lipid-bound Nile Red is 
linearly correlated with the concentration of cellular lipids.36 Moreover, depending on 
the hydrophobicity of the bound lipids, Nile Red displays different emission 
maxima.37 For example, Nile Red-stained neutral lipids like triacylglycerols and 
cholesterol esters, which are the main contents of lipid droplets, fluoresce with an 
emission maximum of ~560 nm, while polar phospholipids like phosphatidylcholine, 
phosphatidylethanolamine and phosphatidylserine, which are the main constituents of 
lipid bilayers, have an emission maximum of ~620 nm. Hence, this sensitive 
fluorescent stain can provide important information about alterations in the levels of 
these lipid classes, which is a composite representation of the highly dynamic lipid 
flux from various segments of cellular lipid homeostasis (uptake, synthesis, transport, 
storage, remodeling, and degradation). As shown in Figure 3, three of the 
fluorobenzyl analogues (12–14) significantly reduced the cellular levels of both 
phospholipids and neutral lipids when compared to the DMSO control. Similar results 
were observed in the metastatic prostate cancer cell line PC-3 (see Supporting 
Information, Figure S50). For comparison, the known acetyl-CoA carboxylase 
inhibitor TOFA, which antagonizes de novo fatty acid synthesis,38 reduced the 
cellular neutral lipid content to similar levels as 12 and 13, while the phospholipid 
levels remained unaffected (Figure 3). It is noteworthy that the ortho-substituted 
fluorobenzyl analogue 14 displayed a significantly reduced inhibitory activity towards 
the cellular neutral lipid levels in comparison to the para and meta fluoro-substituted 
isomers 12 and 13 (Figure 3A). These data indicated that the substitution pattern on 
the benzyl ring is important for the antagonistic activity. The present discovery that 
the fluorobenzyl analogues reduced cellular lipid levels in LNCaP and PC-3 cells 
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suggested that they affect one or multiple aspects of lipid homeostasis. The 
dysregulation of lipid metabolism is one of the most important metabolic hallmarks of 
cancer and is critical for the pathogenesis of cancer.39 For example, most types of 
cancer synthesize almost all of their required saturated and mono-unsaturated fatty 
acids de novo through enhanced lipogenesis despite the abundance of exogenous 
dietary fatty acids. This lipogenic switch occurs early during the transformation into 
cancerous cells and becomes critical for cancer cell survival during cancer 
progression. Mounting evidence demonstrates that the dysregulation of lipid 
metabolism in cancer provides excellent chemotherapeutic targets with the potential 
for a large therapeutic index.39 Hence, future experiments will investigate the 
molecular mechanism of the antilipogenic phenotype of the fluorobenzyl analogues. 
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EXPERIMENTAL SECTION 
General Experimental Procedures. Melting points were determined on a Cole-
Palmer melting point apparatus and are uncorrected. UV spectra were recorded on a JASCO 
V-650 UV/vis spectrophotometer. FTIR data were recorded using a Universal Attenuated 
Total Reflectance Two (UATR) attachment on a Perkin-Elmer spectrophotometer. NMR 
spectra were recorded at 30 °C on a Varian 600 MHz Unity INOVA spectrometer that was 
equipped with a triple resonance cold probe. The 1H and 13C NMR chemical shifts were 
referenced to the solvent peak for DMSO-d6 at δH 2.50 and δC 39.5, respectively. LRESIMS 
were recorded on a Waters ZQ mass spectrometer. HRESIMS data were recorded on a 
Bruker Daltronics Apex III 4.7e Fourier-transform mass spectrometer. Thin-layer 
chromatography (TLC) was performed on Merck silica gel 60 F254 pre-coated aluminum 
plates and was observed using UV light. Alltech Davisil silica 30–40 μm 60 Å was used for 
pre-adsorption of the crude reaction products and was packed into an open glass column (35 
× 70 mm) for silica gel flash chromatography. X-ray diffraction data were collected on an 
Oxford-Diffraction Gemini S Ultra CCD diffractometer utilizing CrysAlis software. All 
solvents used for chromatography, UV, and MS were Lab-Scan HPLC grade, and the H2O 
was Millipore Milli-Q PF filtered. All the reagents were purchased from Sigma Aldrich and 
used without further purification. 
 
Synthesis of Methyl(3-chloro-4-hydroxyphenyl)acetate. 3-Chloro-4-
hydroxyphenylacetic acid (1, 1.5 g, 0.0075 mol, Sigma Aldrich, 99%) was dissolved in 
anhydrous MeOH (1 mL), and a crystal of pTsOH was added and the mixture was stirred at 
room temperature for 48 h.40, 41 Excess solvent was removed under N2 and the resulting crude 
mixture was partitioned between CH2Cl2 (2 × 100 mL) and saturated NaHCO3 (100 mL). The 
CH2Cl2 layer was dried over anhydrous MgSO4 then the solvent removed under reduced 
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pressure to yield methyl(3-chloro-4-hydroxyphenyl)acetate (2, 1.43 g, 95%) as a pale-brown 
gum. NMR and MS data were consistent with literature values.42 
 
Generation of the Amide Library. Methyl(3-chloro-4-hydroxyphenyl)acetate (2, 50 
mg, 0.25 mmol) and the relevant primary amine (0.5 mL) were added together and stirred for 
16 h at room temperature. The reaction mixture was dried under N2 and then high-vacuum 
before being redissolved in CH2Cl2-MeOH (1:1) and pre-adsorbed to silica (~ 1 g) overnight. 
Two different purification conditions were used during these studies. The first method was 
applied to the neutral amide analogues (3–15) and included the pre-adsorbed material being 
dry packed onto a CH2Cl2 equilibrated silica flash column (35  70 mm) and subsequently 
flushed using CH2Cl2 (100 mL), 95:5 CH2Cl2-MeOH (100 mL), 90:10 CH2Cl2-MeOH (100 
mL), and 80:20 CH2Cl2-MeOH (100 mL). The second method was applied to the basic 
analogues (16–22) whereby the pre-adsorbed material was dry packed onto a CH2Cl2 
equilibrated silica flash column and subsequently flushed using 100:1 CH2Cl2-TEA (101 
mL), 95:5:1 CH2Cl2-MeOH-TEA (101 mL), 90:10:1 CH2Cl2-MeOH-TEA (101 mL), and 
80:20:1 CH2Cl2-MeOH-TEA (101 mL). For both purification methods, 10 fractions were 
collected from each eluent flush, and then analyzed by both TLC and 1H NMR spectroscopy 
with only high-purity fractions combined and added to the screening library. The physical 
and spectroscopic data of compounds 3–11 and 15–22 are summarized in the Supporting 
Information (S44). 
2-(3-Chloro-4-hydroxyphenyl)-N-(4-fluorobenzyl)acetamide (12): light brown 
needles; (45.2 mg, 66%); mp 175–178 °C; UV (MeOH) (log ε) 233 (3.81), 282 (3.39) nm; IR 
νmax 1607, 1592, 1538, 1509, 1421, 1210, 1157, 1058 cm–1; 1H NMR (600 MHz, DMSO-d6) 
δH 3.38 (2H, s, H-7), 4.25 (2H, d, J = 6.0 Hz, H-9), 6.91 (1H, d, J = 8.3 Hz, H-5), 7.03 (1H, 
dd, J = 8.3, 2.1 Hz, H-6), 7.12 (2H, m, H-12, H-14), 7.24 (1H, d, J = 2.1 Hz, H-2), 7.26 (2H, 
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dd, J = 8.2, 5.9 Hz, H-11, H-15), 8.47 (1H, t, J = 6.0 Hz, NH-8), 9.96 (1H, br s, OH-4); 13C 
NMR (150 MHz, DMSO-d6) δC 41.0 (C-7), 41.6 (C-9), 114.9 (2C, d, 2JCF = 20.8 Hz, C-12, 
C-14), 116.4 (C-5), 119.3 (C-3), 128.0 (C-1), 128.6 (C-6), 129.2 (2C, d, 3JCF = 8.2 Hz, C-11, 
C-15), 130.2 (C-2), 135.6 (d, 4JCF = 2.3 Hz, C-10), 151.6 (C-4), 161.2 (d, 1JCF = 240.8 Hz, C-
13), 170.2 (C-8); (–)-LRESIMS m/z  292 (100), 294 (30) [M – H]–; (+)-LRESIMS m/z  294 
(100), 296 (30) [M + H]+; (–)-HRESIMS m/z 292.0550 [M – H]– (calcd for C15H12ClFNO2, 
292.0546). 
 
2-(3-Chloro-4-hydroxyphenyl)-N-(3-fluorobenzyl)acetamide (13): brown solid; (21.4 
mg, 34%); UV (MeOH) (log ε) 232 (3.79), 282 (3.33) nm; IR νmax 1610, 1542, 1510, 1489, 
1420, 1338, 1285, 1242, 1199, 1143, 1056 cm–1; 1H NMR (600 MHz, DMSO-d6) δH 3.39 
(2H, s, H-7), 4.28 (2H, d, J = 6.0 Hz, H-9), 6.90 (1H, d, J = 8.2 Hz, H-5), 7.03 (1H, dd, J = 
8.2, 2.2 Hz, H-6), 7.03 (2H, overlap, H-11, H-13), 7.06 (1H, d, J = 7.9 Hz, H-15), 7.25 (1H, 
d, J = 2.2 Hz, H-2), 7.33 (1H, ddd, J = 7.9, 7.9, 6.1 Hz, H-14), 8.50 (1H, t, J = 6.0 Hz, NH-8), 
9.95 (1H, br s, OH-4); 13C NMR (150 MHz, DMSO-d6) δC 41.0 (C-7), 41.7 (C-9), 113.4 (d, 
2JCF = 20.9 Hz, C-13), 113.7 (d, 2JCF = 21.6 Hz, C-11), 116.4 (C-5), 119.3 (C-3), 123.1 (d, 
4JCF = 2.9 Hz, C-15), 128.0 (C-1), 128.6 (C-6) 130.1 (d, 3JCF = 9.2 Hz, C-14), 130.2 (C-2), 
142.5 (d, 3JCF = 7.1 Hz, C-10), 151.6 (C-4), 162.2 (d, 1JCF = 241.6 Hz, C-12), 170.3 (C-8); (–
)-LRESIMS m/z  292 (100), 294 (30) [M – H]–; (+)-LRESIMS m/z  294 (100), 296 (30) [M + 
H]+; (–)-HRESIMS m/z 292.0548 [M – H]– (calcd for C15H12ClFNO2, 292.0546). 
 
2-(3-Chloro-4-hydroxyphenyl)-N-(2-fluorobenzyl)acetamide (14): off-white solid 
(11.4 mg, 16%); UV (MeOH) (log ε) 231 (3.86), 282 (3.40) nm; IR νmax 1609, 1542, 1494, 
1419, 1284, 1236, 1199, 1056 cm–1; 1H NMR (600 MHz, DMSO-d6) δH 3.37 (2H, s, H-7), 
4.30 (2H, d, J = 6.0 Hz, H-9), 6.88 (1H, d, J = 8.2 Hz, H-5), 7.02 (1H, dd, J = 8.2, 2.2 Hz, H-
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6), 7.14 (1H, overlap, H-14), 7.15 (1H, overlap, H-12), 7.23 (1H, d, J = 2.2 Hz, H-2), 7.28 
(1H, overlap, H-15), 7.30 (1H, overlap, H-13), 8.45 (1H, t, J = 6.0 Hz, NH-8), 9.96 (1H, br s, 
OH-4); 13C NMR (150 MHz, DMSO-d6) δC 36.0 (d, 3JCF = 4.6 Hz, C-9), 40.8 (C-7), 115.0 (d, 
2JCF = 20.6 Hz, C-12), 116.4 (C-5), 119.2 (C-3), 124.2 (d, 4JCF = 3.4 Hz, C-14), 125.9 (d, 2JCF 
= 15.2 Hz, C-10), 127.9 (C-1), 128.5 (C-6), 128.7 (d, 3JCF = 8.1 Hz, C-13), 130.1 (C-2), 129.5 
(d, 3JCF = 4.5 Hz, C-15), 151.6 (C-4), 160.0 (d, 1JCF = 244.5 Hz, C-11), 170.2 (C-8); (–)-
LRESIMS m/z  292 (100), 294 (30) [M – H]–; (+)-LRESIMS m/z  294 (100), 296 (30) [M + 
H]+; (–)-HRESIMS m/z 292.0549 [M – H]– (calcd for C15H12ClFNO2, 292.0546). 
 
Cellular Lipid Content Analysis. LNCaP and PC-3 cells were obtained from the 
American Type Cell Culture Collection. Both cells were seeded in optical 96 well plates 
(ibidi) at 4,000 cells/well and 3,000 cells/well, respectively in phenol-red free RPMI-1640 
medium (Thermo Fisher Scientific) supplemented with 5% CSS (Thermo Fisher Scientific) 
for 72 h. The evaluation of the cellular lipid content was performed as previously described.43 
Briefly, after treatment for 48 h with the indicated compounds at 10 M in 0.3% DMSO, the 
medium was removed, and cells were fixed in 4% paraformaldehyde for 20 min on ice. Cells 
were then stained for 20 min at room temperature protected from light in 100 L PBS 
containing 1.0 g/mL DAPI [2-(4-amidinophenyl)-1H-indole-6-carboxamidine, Sigma 
Aldrich] and 0.25 g/mL Nile Red (Sigma Aldrich). Images in the DAPI, Cy3 and Cy5 
channels were acquired on an INCell Analyzer 2200 system (GE Healthcare) at 10 
magnifications. Image segmentation and quantitation of cellular mean fluorescence intensities 
of phospholipids (Cy5) and neutral lipids (Cy3) of ~ 1500 cells per treatment were performed 
with CellProfiler software (Broad Institute).44,45 Statistical significance was analyzed with 
GraphPad Prism (GraphPad Software) by one-way ANOVA with Dunnett’s multiple 
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comparison test. Control cells were treated with the equivalent dose of DMSO (negative 
control) or TOFA [5-(tetradecyloxy)-2-furoic acid, Sigma Aldrich] as the positive control. 
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Scheme 1. Reagents and conditions. (i) anhydrous MeOH, pTsOH (cat.), rt, 24 h. (ii) amine, 
rt, 16 h. 
 
 
Figure 1. Chemical structures of the amide library 3–22. 
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Figure 2. ORTEP drawing for compound 12. 
 
A                                                                                     B 
 
Figure 3. (A) Neutral lipid and (B) phospholipid content of LNCaP cells treated for 
48 h with 10 M of TOFA (positive control) or the library compounds 12–14. The mean 
fluorescence intensities (FI) of cellular neutral lipids and phospholipids of Nile Red-stained  
LNCaP cells were quantified with CellProfiler (n~1500 cells, mean  ±  SD, one-way ANOVA 
with Dunnett’s multiple comparison test, ns = not significant, *** p < 0.001). 
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